



7th Framework Programme FP7 "Health" NCPs

Diana Ivanova, NCP "Health"
Medical University - Varna
Bulgaria





Summary

- **Overview of FP7**
- **Collaborative research in the Health theme**
- **Timescale to funding**
- **Who can help?**





The role of EC is to promote collaborative research

EC promotes coordination of national funding programmes and cooperation:

- between countries:
 - multinational consortia (EU-27 MS + associated countries)
 - researchers from any country in the world can participate;
- between different types of organizations: universities, research centres, SMEs, large companies, etc.
- between disciplines: focus on translational research





The Framework Programme is European Commission's main funding scheme for funding collaborative R&D

- Framework Programme initiated in 1984
- Current Framework Programme (FP7) runs 2007- 2013
- Funds for FP7: €50.5 billion
- Open to any legal entity in a Member State, Associated Country or Third Country





FP7 is split into four 'Specific Programmes'

**Co-operation – Collaborative Research, Joint Technology Initiatives, e.g.: the Innovative Medicines Initiative (IMI)
€32,365m**

**Ideas programme - European Research Council (ERC)
€7,460m**

**People - Human Potential and Science Careers
€4,728m**

**Research Capacities - Infrastructures, SME, Regions & Potential
€4,217m**



Cooperation: Collaborative research in FP7

1.	Health		6.1
2.	Food, Agriculture, and Biotechnology	1.9	
3.	Information and Communication Technologies		9.1
4.	Nanosciences, Nanotechnologies, Materials and New Production Technologies		3.5
5.	Energy		2.3
6.	Environment (including Climate Change)		1.9
7.	Transport (including Aeronautics)		4.2
8.	Socio-economic Sciences and Humanities		0.6
9.	Security		
10.	Space		2.8

Total for collaborative research

€32.4 billion



Cooperation: Collaborative research in Health: € 6 billion

The objective of the health research programme is:

- **To improve health** of European citizens
- **To increase competitiveness and innovative capacity** of European health-related industries and businesses
- **To address global health issues**, like emerging epidemics
- **European collaboration with developing countries** to allow them develop research capacities



Why will citizens benefit from European health research?

- Translational research (basic discoveries → clinical applications)
- Development and validation of new therapies
- Methods for health promotion and prevention (promotion of healthy aging, diagnostic tools and medical technologies)
- Sustainable and efficient healthcare system



From FP6 to FP7:

- Continuity;
- Broader scope;
- Less focus on genomics;
- Emphasis on translational research;
- Health policy driven research strongly reinforced.
- New: emerging epidemics, obesity, chronic diseases, biomedical technology & engineering.



Why will researchers benefit from European health research?

Activities in 3 main areas:

1. Biotechnology, generic tools and medical technologies for human health
2. Translating research for human health
3. Optimizing the delivery of healthcare to European citizens



Why will researchers benefit from European health research?

Two other issues will be addressed across all activities:

- Child health
- The health of the ageing population

- ✓ Throughout all work programme topics, where appropriate.
- ✓ Through specific topics



European-funded health research will focus on:

1. Biotechnology, generic tools and technologies for human health

(a) High-throughput research
enhancing data generation, standardisation,
acquisition & analysis

(b) Detection, diagnosis and monitoring
with emphasis on non-invasive or minimally
invasive approaches



European-funded health research will focus on:

1. Biotechnology, generic tools and technologies for human health

(c) Prediction of suitability, safety and efficacy of therapies

development and validation of parameters, tools, methods and standards (mainly through IMI) and alternatives to animal testing

(d) Innovative therapeutic approaches and intervention

gene and cell therapy, regenerative medicine, immunotherapy, vaccines.



European-funded health research will focus on:

2. Translating research for human health

- (a) Integration of biological data and processes:
large-scale data gathering, systems biology
- (b) Research on the brain and related diseases,
human development and ageing



European-funded health research will focus on:

2. Translating research for human health

- (c) Translational research in infectious diseases:
to confront major threats to public health:
antimicrobial drug resistance, HIV/AIDS, malaria
and tuberculosis, emerging epidemics, neglected
infectious diseases

- (d) Translational research in major diseases:
cancer, CVD, diabetes/ obesity,
rare diseases, and other chronic diseases,
including rheumatoid diseases, arthritis and
musculoskeletal diseases



European-funded health research will focus on:

3. Optimising the delivery of healthcare to European citizens

- (a) Translation of clinical outcome into clinical practice
patient safety, better use of medicines, benchmarking, etc.
- (b) Quality, efficiency and solidarity of health care systems including transitional health care systems and home care strategies
- (c) Enhanced disease prevention and better use of medicines
- (d) Appropriate use of new health therapies and technologies



Why will industry and SMEs benefit from European health research?

- Special emphasis and measures for:
 - SMEs
 - Participation encouraged in all areas
 - Special topics for SMEs
 - Support actions
 - Research-based SMEs are the main economic drivers of healthcare, biotechnology and medical technologies
 - Strong EU-based biomedical research will enhance competitiveness of the European pharmaceutical and healthcare industries

SMEs participation: Dr. Ludovica Serafini

Tel. +32 2 295 6759

Email: ludovica.serafini@ec.europa.eu



Special emphasis and measures for:

- **International Cooperation**
 - Participation possible in all areas
 - Special International Cooperation Actions (SICA)
 - Coordination or Support actions

International Cooperation: Dr. Indridi Benediktsson

Tel. +32 2 299 3137

Email: indridi.benediktsson@ec.europa.eu



Innovative Medicines Initiative (IMI)

The Innovative Medicines Initiative is a proposed Public-Private Partnership (PPP) involving the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Commission.

Innovative Medicines Initiative: Dr. Irene Norstedt

Tel. +32 2 296 9527

Email: irene.norstedt@ec.europa.eu

http://ec.europa.eu/research/health/imi/index_en.html



Topics for second call (18 September 2007):

1. Biotechnology, generic tools and technologies

- SME-driven collaborative research projects for developing tools and technologies for high-throughput research (FRP targeted to SMEs)
- Standardisation and improvement of pre-analytical procedures for in vitro diagnostics “involvement of industry recommended” (IP).
- High throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical presentation “should offer opportunities for exploitation, preferably through SMEs” (FRP).



Topics for second call (18 September 2007):

1. Biotechnology, generic tools and technologies

Gene therapy

- Development of emerging gene therapy tools and technologies for clinical application (IP).
- Gene therapy tools targeting the central nervous system (FRP).

Regenerative medicine

- Stem cell lines for cell-based therapies (one or more IP).
- Development of stem cell culture conditions (FRP).
- Stem cells for kidney regeneration (FRP).
- Adding value to EU stem cell therapy research: scientific communication and future perspectives (CA or SA).



Topics for second call (18 September 2007):

2. Translating research for human health

- Novel targets for drugs against Gram negative bacteria (FRP).
- Host-pathogen interactions in infections by *Streptococcus pneumoniae* (FRP).
- An integrated platform for development and clinical evaluation of point-of-care diagnostic devices for microbial detection, antibiotic susceptibility determination and biomarkers (IP).
- Molecular epidemiology to control nosocomial and community spreading of highly virulent multi-drug resistant strains of bacterial pathogens (FRP).
- Health and economic cost of antimicrobial resistance (CA or SA).
- Conference on genetic and biochemical tools for post-genomic physiological analysis of *Staphylococcus* (CA or SA).



Topics for second call (18 September 2007):

2. Translating research for human health

- Network on HIV and anti-HIV drug resistance (IP).
- HIV and Hepatitis co-infection (CA or SA).
- Blocking the transmission of malaria: the mosquito vector target (FRP).
- European network for study and clinical management of TB drug resistance (IP).



Topics for second call (18 September 2007):

2. Translating research for human health

SICA topics

- Highly innovative research in HIV/AIDS, malaria and tuberculosis between Indian and European partners.
Targeted Region: India. Other ICPCs are also encouraged to join (FRP).
- Coordination of European research activities with global initiatives, including Public-Private Partnerships.
Targeted Regions: ICPC (CA or SA).
- Next generation of researchers for HIV/AIDS, malaria, tuberculosis and neglected infectious diseases.
Targeted Regions: ICPC (CA or SA).

ICPC: International Cooperation Partner Countries



Topics for second call (18 September 2007):

2. Translating research for human health

- Strengthening research on prediction, identification, modelling and surveillance of newly emerging infectious diseases in humans (IP).
- Definition of research needs and priorities in Europe in the area of Emerging Infectious Epidemics (CA or SA).

SICA topics

- Development of new tools to control infections due to parasites of the Trypanosomatidae family. Targeted regions: ICPC (FRP).
- Development of a Leishmania vaccine. Targeted regions: ICPC (FRP).
- Bioprospecting for drug leads. Target area: ICPC (FRP).



Topics for second call (18 September 2007):

2. Translating research for human health

- Innovative combination clinical trials for multimodal cancer therapy (IP).
- Role of inflammation in tumour initiation and progression (IP).
- Epidemiology of gene-environment interactions involved in carcinogenesis (IP).
- Translating the hypoxic tumour microenvironment (IP).
- ERA-NET on optimisation of the use of cancer registries for cancer research purposes (CA, through a joint call for ERA-NETs across the Themes).

SICA topic

- Studying cancer aetiology in Latin America.
Targeted region: Latin America (FRP).



Topics for second call (18 September 2007):

2. Translating research for human health

- Congenital pathologies affecting the heart (FRP).
- Cell therapies for the treatment of heart ischemia (FRP).
- Early processes in the pathogenesis of chronic inflammatory diseases (IP).

- Nutritional signals and the development of new diabetes/obesity therapeutic agents (FRP).



Topics for second call (18 September 2007):

3. Optimising the delivery of health care to citizens

- Evaluation of disease management programmes (FRP).
- Health systems and long term care of the elderly (FRP).
- Mobility of health professionals (FRP).
- Health care human resource planning in nursing (FRP).
- Clinician working time and patient safety (FRP).
- Health outcome measures and population ageing (FRP).
- Trends of population health (FRP).
- European system of Diagnosis-related groups (FRP).



Topics for second call (18 September 2007):

3. Optimising the delivery of health care to citizens

- Promoting healthy behaviour in children and adolescents (FRP).
- Interventions addressing the gradient of health inequalities (FRP).
- Public health interventions addressing the abuse of alcohol (FRP).
- Improve vaccination coverage (FRP).



Topics for second call (18 September 2007):

3. Optimising the delivery of health care to citizens

Horizontal CA & SA

- Disease networks of centres of reference. Scoping study (SA).
- Effectiveness of health investments. Scoping study (SA).
- Patient mobility and access to information. Scoping study (CA or SA).

- Health Services Research conference (SA).
- Public Health intervention research conference (SA).



Topics for second call (18 September 2007):

3. Optimising the delivery of health care to citizens

SICA topics

- Epidemiological investigations into long-term trends of population health as consequence of socio-economic transitions, including life-style induced health problems. Targeted regions: MPC, Russia, Eastern European and Central Asia (FRP).
- Universal and equitable access to health care and health financing. Targeted regions: MPC, ACP, Asia and Latin America (FRP).
- Health care intervention research – optimising hospital care. Targeted region: Western Balkans (FRP).
- Health care intervention research – improving pre-natal and maternal care. Targeted regions: ACP and MPC (FRP).

MPC: Mediterranean Partner countries

ACP: African, Caribbean and Pacific countries



Topics for second call (18 September 2007):

Across the Health Theme

SICA topic

- Promotion and facilitation of international cooperation in areas relevant to the objectives of this Theme. Targeted regions: ICPC (CA or SA).

Responding to EU policy needs

Paediatric medicinal products

- Adapting off-patent medicines to the specific needs of paediatric populations (FRP) Ref.: www.emea.europa.eu

Drug safety research

- Relative safety of non-steroidal anti-inflammatory drugs (NSAIDs) (FRP).

Framework Convention on Tobacco Control

- Effectiveness of fiscal policies for tobacco control in Europe (FRP).



EC Health Directorate

Director – Dr. Octavi Quintana-Trias

**Medical and Public Health
Research Unit**

•Cancer

•Public Health Sector

Dr. Manuel Hallen

Dr. Maria Vidal

Dr. Kevin McCarthy

manuel.hallen@ec.europa.eu

maria-jose.vidal-
ragout@ec.europa.eu

kevin.mccarthy@ec.europa.eu

Infectious Diseases Unit

•Emerging Infectious
diseases Sector

Dr. Bernard Mulligan

Dr. Anna Lönnroth

bernard.mulligan@ec.europa.eu

anna.lonnroth@ec.europa.eu

**Genomics and Systems
Biology Unit**

Dr. Jacques Remacle

jacques.remacle@ec.europa.eu

Health Biotechnology Unit

Dr. Arnd Hoeveler

arnd.hoeveler@ec.europa.eu

Coordination Unit

Stéphane Hogan

stephane.hogan@ec.europa.eu



Where to find information and help?

Your partner search sites:

http://cordis.europa.eu/fp7/partners_en.html

Your NCPs:

http://cordis.europa.eu/fp7/get-support_en.html

For more information:

http://cordis.europa.eu/fp7/home_en.htm

Experts:

http://cordis.europa.eu/research_openings



Where to find information and help in Bulgaria?

- <http://www.medunion-bg.org/ramkovaprograma.aspx> (Union of Bulgarian Medical Societies)
- <http://7fp.mon.bg> (Ministry of Education and Science)



Bulgarian NCPs Health

BELCHEVA, Iren (Mrs)

Health NCP

Record Control Number: 19864
Update Date: 2007-02-02

Bulgarian Academy of Sciences
Institute of Physiology
Acad.G.Bonchev, block 23
1000
Sofia
BULGARIA

Tel: +359-2-9792151
Fax: +359-2-719109
URL: <http://www.bas.bg>
Email: [Contact](#)
Programme acronym: FP7-HEALTH



Bulgarian NCPs Health

GIRCHEV, Radoslav (Mr)

Health NCP

Record Control Number: 19862
Update Date: 2007-02-02

Medical University
Physiology
15 Ivan Geshov Blvd.
1431
Sofia
BULGARIA

Tel: +359-2-9172690
Fax: +359-2-9520345
URL: <http://www.medfac.acad.bg>
Email: [Contact](#)
Programme acronym: FP7-HEALTH



Bulgarian NCPs Health

JORDANOVA, Albena (Mrs)

Health NCP

Record Control Number: 19863
Update Date: 2007-02-02

Medical University
15 Ivan Geshov Blvd
1431
Sofia
BULGARIA

Tel: +359-2-9172325
URL: <http://www.medfac.acad.bg>
Email: [Contact](#)
Programme acronym: FP7-HEALTH



Bulgarian NCPs Health

MIHAYLOVA-MIKOVA, Sashka (Mrs)

Health NCP

Record Control Number: 19866
Update Date: 2007-02-02

University of Medicine
Microbiology, Viruses and Medical
Genetics
1 Sveti Kliment Ohridski Str.
5800
Pleven
BULGARIA

Tel: +359-6-4884136
Fax: +359-6-4801603
URL: <http://www.mu-pleven.bg>
Email: [Contact](#)
Programme acronym: FP7-HEALTH



Bulgarian NCPs Health

IVANOVA, Diana (Mrs)

Health NCP

Record Control Number: 19865
Update Date: 2007-02-02

Varna University of Medicine
"Prof.Dr.Paraskev Stoyanov"
Department of Pharmacology,
Chemistry and Biochemistry
55 Marin Drinov Street
9002
Varna
BULGARIA

Tel: +359-5-2650061
Fax: +359-5-2650019
URL: <http://www.mu-varna.bg>
Email: [Contact](#)
Programme acronym: FP7-HEALTH

